Home » Newsletters » BioWorld Science

BioWorld Science

May 24, 2022

View Archived Issues

Loss of PHGDH potentiates metastatic dissemination

Kymera Therapeutics presents data on the IRAK4 degrader KT-474 in different cell subsets

Shenzhen Chipscreen Biosciences divulges PD-1/PD-L1 and/or CD80/PD-L1 interaction inhibitors

Idorsia Pharmaceuticals patents new LGALS3 inhibitors

Follicum AB and University of Bradford disclose compounds for skin and hair disorders

Boehringer Ingelheim Pharma KG identifies new EGFR mutant inhibitors

New c-Myc inhibitors presented by Suzhou Kintor Pharmaceuticals

Entrada's EEV treatments progress for Duchenne muscular dystrophy, myotonic dystrophy type 1

AKAP11 is a risk gene shared by bipolar disorder and schizophrenia

Salubris submits CTA in Europe for CTLA-4/IL-15 antibody fusion protein JK-08

FDA grants orphan drug designation to DepYmed's DPM-1001 for Wilson disease

KaliVir and Roche to collaborate on novel oncolytic vaccinia viruses

Aptamer and PinotBio extend collaboration to develop Optimer-drug conjugates

PharmaCyte studies pancreatic cancer therapy to treat malignant ascites

Anti-IL13RA1 eblasakimab reduces neuronal response to proinflammatory cytokines

Research on IL-38 mRNA expression in cancers supports Immunome's development of IMM-ONC-01

Elicio shows AMP vaccination significantly enhances TCR-T antitumor response in tumor model

Quoin enters research agreement with QUT to target VCAM-1:VL-4 interaction to treat scleroderma

Antigen-specific immunotolerance platform shows preclinical proof of concept for Parkinson's disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Sanofi phase III CIDP quit dents Dianthus; C1 mismatch?
BioWorld
Investors in Dianthus Therapeutics Inc. apparently chose to ignore subtleties in the difference between efforts with that firm’s claseprubart vs. those by...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...